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Association of ChemoradiotherapyWith Outcomes Among
PatientsWith Stage I to II vs Stage III Small Cell Lung Cancer
Secondary Analysis of a Randomized Clinical Trial
Ahmed Salem, FRCR; HiteshMistry, PhD; Matthew Hatton, FRCR; Imogen Locke, FRCR;
Isabelle Monnet, MD; Fiona Blackhall, PhD; Corinne Faivre-Finn, PhD
IMPORTANCE There is limited evidence to guide stage I to II small cell lung cancer (SCLC)
treatment.
OBJECTIVE To examine the characteristics and outcomes among patients with stage I to II
SCLC treated with modern chemoradiotherapy.
DESIGN, SETTING, AND PARTICIPANTS In this post hoc secondary analysis of the Concurrent
Once-Daily vs Twice-Daily Radiotherapy Trial (CONVERT), a multicenter phase 3 trial
conducted in patients with limited-stage SCLC from April 7, 2008, to November 29, 2013,
patients with TNM stage I to II SCLC were compared with those with stage III disease. Data
analysis was performed fromNovember 1, 2017, to February 28, 2018.
INTERVENTIONS In CONVERT, patients were randomized to receive twice-daily (45 Gy in 30
fractions) or once-daily (66 Gy in 33 fractions) chemoradiotherapy. Prophylactic cranial
irradiation (PCI) was offered, if indicated.
MAIN OUTCOMES ANDMEASURES The primary trial end point was overall survival (OS). TNM
staging information was collected prospectively; this was an unplanned analysis because
stratification was not performed according to TNM stage.
RESULTS A total of 509 (277 [54.4%]men; mean [SD] age, 61.5 [8.3] years) of 543 patients
(93.7%) with TNM staging information were eligible for this subgroup analysis, and 86 of the
509 (16.9%) had TNM stage I to II disease. Themedian gross tumor volumewas smaller in
patients with stage I to II disease (38.4 cm3; range, 2.2-593.0 cm3) compared with patients
with stage III disease (93 cm3; range, 0.5-513.4 cm3) (P < .001). No other significant
differences were found in baseline and treatment characteristics and chemoradiotherapy
adherence between the 2 groups or the number of patients with stage I to II disease (78
[90.7%]) and stage III disease (346 [81.8%]) who received PCI (P = .10). Patients with stage I
to II disease achieved longer OS (median, 50months [95% CI, 38 to not reachedmonths]
vs 25months [95% CI, 21-29months]; hazard ratio, 0.60 [95% CI, 0.44-0.83]; P = .001)
compared with patients with stage III disease. In patients with stage I to II disease, no
significant survival difference was found between the trial arms (median, 39months in the
once-daily arm vs 72months in the twice-daily arm; P = .38). Apart from lower incidence of
acute esophagitis in patients with stage I to II disease compared with patients with stage III
disease (grade 3, 9 [11.3%] vs 82 [21.1%]; P < .001), the incidences of acute and late toxic
effects were not significantly different.
CONCLUSIONS AND RELEVANCE Patientswith stage I to II SCLC in CONVERT achieved long-term
survival with acceptable toxic effects after chemoradiotherapy and PCI. This study suggests that
patientswith stage I to II small cell lung cancer treatedwithmodern chemoradiotherapy have
better outcomes comparedwith patientswith stage III disease, providing information that
practitioners can potentially give their patients to aid clinical decisions.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT00433563
JAMA Oncol. 2019;5(3):e185335. doi:10.1001/jamaoncol.2018.5335
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S
mall cell lung cancer (SCLC) accounts for 10% to 20%of
lung cancer cases.1 A 2-tier staging system, introduced
bytheVeteransAdministrationLungCancerStudy,2clas-
sifies disease into limited or extensive stage according to
whether the tumor is localized to one hemithorax. On the ba-
sis of several meta-analyses and landmark trials,3-7 standard
treatment for limited-stage SCLC is chemoradiotherapyusing
twice-daily radiotherapy delivered earlywith chemotherapy.
Patients with treatment response should also be offered pro-
phylactic cranial irradiation (PCI).8
TheUnion for InternationalCancerControl/AmericanJoint
Committee on Cancer (UICC/AJCC), based on an Interna-
tional Association for the Study of Lung Cancer analysis, rec-
ommended the use of TNM staging for SCLC in 2009 because
itprovidesadditionalprognostic information.9,10Patientswith
limited-stage SCLC are a heterogeneous population that in-
cludesearly (TNMstages I-II) and locally advanced (TNMstage
III) tumors.
To date, there are no data on the proportion or outcome
of patients with stage I to II disease included in trials that es-
tablishedchemoradiotherapyas standard treatment,6,11,12 lim-
iting theevidence toguidestage I to II SCLCmanagement.Lim-
ited evidence supports a role for surgical resection in patients
with resectable stage I to II SCLC,13-21which is reflected in on-
cology practice guidelines.22-24 However, there is no consen-
sus on the optimal postsurgery adjuvant therapeutic ap-
proach for thesepatients.25,26Thus, the roleof surgery in stage
I to II SCLC is not clearly defined, and international practice is
variable.17,25
The outcome of patients with stage I to II SCLC treated
with chemoradiotherapyhasnot been reported, toour knowl-
edge, since the adoption of TNM staging, the use of flude-
oxyglucose F 18–labeled positron emission tomography
(FDG-PET) for staging, the omission of elective nodal irradia-
tion, and thewidespreaduseof conformal radiotherapy.Toad-
dress these issues and inform clinical practice, we performed
a secondary analysis of the Concurrent Once-Daily vs Twice-
Daily Radiotherapy Trial (CONVERT) (ClinicalTrials.gov
identifier:NCT00433563) toestablish thecharacteristics, treat-
ment, and outcomes among patients with stage I to II SCLC.
CONVERT was a randomized clinical trial that assigned pa-
tients with limited-stage SCLC and good performance status
to receive twice-daily or once-daily radiotherapy concur-
rently with chemotherapy. CONVERTwas designed to estab-
lish a standard chemoradiotherapy regimen for limited-stage
SCLC, demonstrating that survival outcomeswerenot signifi-
cantly different between twice-daily and once-daily radio-
therapy, with lower than expected toxic effects.4
Methods
Study Design
Full details of the CONVERT design were previously
published.27 In summary, CONVERTwas amulticenter, inter-
national, randomized, phase 3 trial. Eligible patients were 18
yearsorolder,hadhistologicallyorcytologicallyconfirmedlim-
ited-stage SCLC (Veterans Administration Lung Cancer Study
definition),2 andhad anEasternCooperativeOncologyGroup
performance status of 0 to 1. Patientswith a performance sta-
tus of 2 because of cancer-related symptomswere included at
the discretion of the local investigator. All patients under-
went baseline physical examination, chest radiography, tho-
rax and upper abdominal computed tomography (CT), brain
imaging (CT or magnetic resonance imaging), and complete
blood cell count and biochemical profile. Patients were re-
quired to have satisfactory pulmonary functions (forced ex-
piratory volume in 1 second >1 L/40% predicted, transfer fac-
tor for carbonmonoxide>40%predicted). Amaximumofone
of the following adverse serum biochemical findings was
allowed: alkaline phosphatase level more than 1.5 times the
upper limit of normal, sodium level less than the lower limit
of normal, and lactate dehydrogenase level greater than the
upper limit of normal. Staging FDG-PET was allowed but not
mandated. This trial was conducted following National
Research Ethics Service Committee North West–Greater
Manchester Central approval in accordance with the Decla-
ration of Helsinki28 and good clinical practice guidelines. All
patients provided written informed consent, and data were
deidentified. Additional trial details can be found in the pro-
tocol in Supplement 1.
Tumor and nodal stage data were collected at the time of
entry into the trial according toAJCC’sCancer StagingManual,
7th edition.29This current analysiswas anunplanned second-
ary analysis of patients with TNM stage I to II SCLC because
stratification was not performed according to TNM stage in
CONVERT. We hypothesized that the outcomes among these
patients would be significantly superior to those among
patients with stage III disease. We analyzed data from
CONVERT toestablish the characteristics, treatment, andout-
comes of patients with stage I to II SCLC compared with
patients with stage III disease.
Treatment and Follow-up
From April 7, 2008, to November 29, 2013, a total of 547 pa-
tients were randomly assigned (usingminimizationmethod)
1:1 to receive concurrent twice-daily radiotherapy (45Gy in 30
twice-daily fractions for 3 weeks, 5 days per week [to convert
Key Points
Question What are the characteristics and outcomes among
patients with stage I to II small cell lung cancer treated with
chemoradiotherapy?
Findings In this secondary analysis of the Concurrent Once-Daily
vs Twice-Daily Radiotherapy Trial, among 509 patients, those with
stage I to II small cell lung cancer achieved longer overall survival
than did patients with stage III disease, with acceptable adverse
effects after chemoradiotherapy and prophylactic cranial
irradiation.
Meaning The findings suggest that patients with stage I to II small
cell lung cancer treated with modern chemoradiotherapy have
better outcomes compared with patients with stage III disease,
providing information that practitioners can potentially give to
their patients to aid clinical decisions.
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gray to rad, multiply by 100]) or once-daily radiotherapy (66
Gy in 33 daily fractions for 6.5 weeks, 5 days per week) from
day 22 of chemotherapy cycle 1. A total of 543 patients were
included in the modified intention-to-treat survival analysis
in CONVERT (273 in the twice-daily radiotherapy group and
270 in theonce-daily radiotherapy group). Four patientswere
lost to follow-up because centers did not return their case re-
port forms. Detailed trial results were published previously.4
Data analysis for this secondary analysiswas performed from
November 1, 2017, to February 28, 2018.
Three-dimensional conformal radiotherapy was man-
dated, and intensity-modulated radiotherapy was per-
mitted. Inhomogeneity corrections were applied during the
radiotherapy process. Elective nodal irradiation was not al-
lowed.A radiotherapyquality assuranceprogrammanagedby
theUKNationalCancerResearch InstituteRadiotherapyTrials
Quality Assurance team was integrated into this trial.27 Che-
motherapywas identical in both arms and consisted of 4 to 6
cycles (center choice) of cisplatin, 25mg/m2 intravenously on
days 1 to 3 or 75 mg/m2 intravenously on day 1, and etopo-
side, 100mg/m2 intravenously ondays 1 to 3 repeated every 3
weeks. Prophylactic cranial irradiation was offered to pa-
tients without evidence of progressive disease on CT (within
4weeks of cycle 4) no later than 6weeks after the last chemo-
therapy cycle. The PCI dose and fractionationwere left to the
discretion of the local investigator. Clinical follow-up assess-
ments consistedofweekly reviewuntil resolutionof acute ad-
verse effects, then 3-monthly reviews until 1 year after ran-
domization and 6-monthly reviews thereafter. Thorax and
upperabdominalCTwas requiredat6and12monthsafter ran-
domization and thereafter as clinically indicated. Radiologic
response was assessed using Response Evaluation Criteria in
Solid Tumours.30
Statistical Analysis
The primary trial end point was overall survival (OS) (defined
as time fromrandomization todeath fromanycause). Second-
ary endpointswere local progression-free survival (defined as
time fromrandomization to first clinical or radiologic evidence
of local progressionordeath) andmetastasis-free survival (de-
fined as time from randomization to first clinical or radiologic
evidence of distant metastasis or death), Common Terminol-
ogyCriteria forAdverseEvents (version3.0)31 toxic effects, and
chemotherapy and radiotherapy adherence. Acute toxic ef-
fectsweredefinedas thoseoccurring fromchemotherapycycle
1 to 3months after completion,whereas late toxic effectswere
defined as those occurring between 3months and2years after
completion of treatment.
Baselineand treatmentcharacteristics, acuteand late toxic
effects, and chemoradiotherapy adherence for patients with
stage I to II and stage III SCLC were compared using the χ2 or
Wilcoxon rank sumtest.Kaplan-Meier curveswereplotted for
each group and survival compared using the Mantel-Cox
version of the log-rank test. A competing risk regression
analysis, using Fine and Gray’s method,32 was used to
assess the correlation between stage and site of tumor pro-
gression in which the competing event was death. Subdistri-
bution hazard ratios (HRs) and P values from the Wald test
were reported. For all HRs, the proportionality assumption
was assessed using Schoenfeld residual plots. In this sub-
group analysis, results were reported for all patients on an
intention-to-treat basis. P < .05 (2-sided) was considered to
be statistically significant. All conducted statistical analyses
were reported andwere performed inR, version 3.4.1 (https://
www.r-project.org).
Results
A total of 509 of 543 patients (93.7%)with TNMstaging infor-
mationwere eligible for this secondary analysis, and86of the
509 (16.9%) had TNM stage I to II disease. Of these 86 pa-
tients, 4patients (4.7%)were stagedashavingTNMstage Idis-
ease and 82 (95.3%) as having TNM stage II disease. Thirty-
eight patients (44.2%) presented with node-positive disease
(N1). A breakdown of tumor and nodal staging for these pa-
tients is given in eTable 1 in Supplement 2. Thirty-five pa-
tients (40.7%)were randomly assigned to receive twice-daily
radiotherapy and 51 (59.3%) to receive once-daily radio-
therapy (Table 1).Table2gives thebaselineandtreatmentchar-
acteristics for both groups. The median gross tumor volume
was significantly smaller in patients with stage I to II disease
(38.4 cm3; range, 2.2-593.0 cm3) comparedwithpatientswith
stage III disease (93 cm3; range 0.5-513.4 cm3; P < .001). No
other significant differenceswere found inbaseline and treat-
ment characteristics between the 2 groups or the proportion
of patients with stage I to II (78 [90.7%]) and stage III (346
[81.8%]) SCLC who received PCI (P = .10). Baseline and treat-
ment characteristics for each trial arm inbothgroupsare given
in eTable 2 in Supplement 2.









Twice daily 35 (40.7) 219 (51.8)




79 (91.9) 382 (90.3)
Sequential
chemoradiotherapy
2 (2.3) 7 (1.7)
No radiotherapy 5 (5.8) 34 (8.0)
No. of treatment cycles
delivered
0 1 (1.2) 4 (0.9)
1 4 (4.7) 23 (5.4)
2 2 (2.3) 10 (2.4)
3 7 (8.1) 36 (8.5)
4 55 (64.0) 247 (58.4)
5 2 (2.3) 14 (3.3)
6 6 (7.0) 89 (21.0)
Included in survival analysis 86 423
Included in toxic effects analysis 85 412
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The survival analysis included 86 patients with stage I to
II disease and 423 patients with stage III disease. Median OS
was 50 months (95% CI, 38 months to not reached) in pa-
tients with stage I to II disease and 25 months (95% CI, 21-29
months) in patients with stage III disease (HR, 0.60; 95% CI,
0.44-0.83; P = .001). Two-year OS was 64% (95% CI, 54%-
75%) inpatientswith stage I to II disease vs 51% (95%CI, 46%-
56%) in patients with stage III disease. Five-year OS was 49%
(95%CI, 39%-62%) inpatientswith stage I to II disease vs 28%
(95% CI, 23%-34%) in patients with stage III disease.
Radiologic tumor response (defined as complete or par-
tial response on any follow-up CT) was not significantly dif-
ferent between patients with stage I to II disease (76%; 95%
CI, 66%-83%) andpatientswith stage III disease (77%;95%CI,
73%-81%) (P = .90). At the time of analysis, 35 of 86 patients
(40.7%)withstage I to IIdiseaseand243of423patients (57.4%)
with stage III disease had disease progression. eTable 3 in
Supplement 2 lists the type of progression sites (ie, locore-
gional vs distant) in the 2 groups and the patients who were
dead at the timeof analysis. eTable 4 in Supplement 2 lists the
sites of tumor progression in patientswith stage I to II disease
and patientswith stage III disease. Competing risk regression
showed that although locoregionalprogressionwas similarbe-
tween the 2 groups (subdistribution HR, 1.29; 95% CI, 0.70-
2.35; P = .41), distant progression was significantly more
common inpatientswith stage III disease (subdistributionHR,
1.60; 95% CI, 1.02-2.51; P = .04). Median local progression-
free survivalwas38months (95%CI,21months tonot reached)
inpatientswith stage I to II diseasevs 17months (95%CI, 15-20
months) in patients with stage III disease (HR, 0.63; 95% CI,
Table 2. Baseline and Treatment Characteristics of the 2 Study Groupsa
Characteristic
Patients With Stage I-II
Disease (n = 86)
Patients With Stage III Disease
(n = 423) P Value
Age, median (range), y 62 (29-77) 62 (34-81) NA
Sex
Male 51 (59.3) 226 (53.4)
.38b
Female 35 (40.7) 197 (46.6)
Smoking history
Never 2 (2.3) 4 (0.9)
.33bEx-smoker 49 (57.0) 269 (63.6)
Current smoker 35 (40.7) 150 (35.5)
ECOG PS
0 49 (57.0) 184 (43.5)c
.06b1 34 (39.5) 226 (53.5)
c
2 3 (3.5) 13 (3.1)c
MRC dyspnea score
0 38 (44.2) 139 (32.9)
.24b
1-2 35 (40.7) 215 (50.8)
3-4 8 (9.3) 40 (9.4)
Not assessed 5 (5.8) 29 (7)
Staging FDG-PET
No 28 (32.6) 189 (44.7)
.10bYes 58 (67.4) 233 (55.1)
c
Not known 0 1 (0.2)c
Planned No. of chemotherapy cycles
4 60 (69.8) 287 (67.8)
.82b
6 26 (30.2) 136 (32.2)
GTV, median (range), cm3 38.4 (2.2-593.0) 93 (0.5-513.4) <.001d
Concurrent 79 (91.9) 382 (90.3)
.72bSequential 2 (2.2) 7 (1.6)
No radiotherapy 5 (5.8) 34 (8.0)
IMRT
Yes 14 (16.3) 67 (15.8)
>.99b
No 72 (83.7) 356 (84.2)
Prophylactic cranial irradiation
Yes 78 (90.7) 346 (81.8)
.10bNo 6 (7.0) 59 (13.9)
Missing data 2 (2.2) 18 (4.3)
Minimum PTV dose, median (range),
%
90.0 (32-100) 87.5 (0-100)
.05d





tomography; GTV, gross tumor
volume; IMRT, intensity-modulated
radiation therapy, MRC, Medical
Research Council; PTV, planning
target volume.
a Data are presented as number
(percentage) of patients unless
otherwise indicated.
bχ2 Test.
c Percentages do not sum to 100%
because of approximation.
dWilcoxon rank sum test.
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0.46-0.85months;P = .003), andmedianmetastatic progres-
sion-free survival was 40 months (95% CI, 24 months to not
reached) inpatientswithstage I to IIdiseasevs 16months (95%
CI, 14-19months) in patients with stage III disease (HR, 0.58;
95%CI,0.42-0.79;P < .001). These results andadditional out-
come data are shown in the Figure and Table 3.
Thedifference inOSbetweenpatientswith stage I to II dis-
ease and those with stage III disease was upheld irrespective
of trial arm (eFigure, A and B in Supplement 2). However, in
patientswith stage I to II disease, therewas no significant dif-
ference inOSbetweentrial arms (medianof39months inonce-
daily vs 72 months in twice-daily arm; P = .38) (eFigure, C in
Supplement 2). Similarly, there was no difference in OS be-
tween patients with stage I to II disease staged with or with-
out FDG-PET (median of 50 months vs 40 months; P = .69)
(eFigure, D in Supplement 2).
The optimal number of fractions, as defined per protocol
(30 fractions in the twice-daily arm and 33 in the once-daily
arm),27were delivered in 69 patients (80.2%) in the stage I to
II groupand314patients (74.2%) in thestage III group (P = .60).
There were no significant differences in the delivered radio-
therapy dose (≥60 Gy to 90 [90.3%] in the once-daily arm vs
≥44Gy to 362 [85.6%] in the twice-daily arm;P = .11) (eTable 5
in the Supplement 2),minimumplanning target volumedose
(90.0%vs87.5%;P = .05) (Table2),ordeliverednumberofche-
motherapy cycles (4 cycles in 55 [64.0%] vs 247 [58.4%] and
6 cycles in 6 [7.0%] vs 89 [21.0%]; P = .98) (Table 1) between
patients with stage I to II disease and those with stage III
disease.
Apart fromasignificantly lower incidenceofacuteesopha-
gitis in patientswith stage I to II disease comparedwith those
with stage III disease (grade ≥3, 9 [11.3%] vs 82 [21.1%];
P < .001), the incidences of acute and late treatment-related
toxic effects were not significantly different between the 2
groups (eTables 6 and 7 in Supplement 2).
Discussion
Limited-stage SCLC prognosis is poor, with modest survival
improvement during the past decades mainly because of
Figure. Overall Survival and Local andMetastatic Progression-Free
Survival in the 2 Groups
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Data represent patients treated with both once-daily and twice-daily
radiotherapy. HR indicates hazard ratio.
Table 3. Comparison of Outcomes Between the 2 Groups
Outcome








1 83 (75-91) 79 (75-83)
.001
2 64 (54-75) 51 (46-56)
4 51 (42-64) 32 (27-37)




1 78 (70-87) 68 (63-72)
.003
2 56 (46-67) 41 (37-46)
4 47 (37-59) 29 (25-34)




1 74 (66-84) 62 (57-67)
<.001
2 59 (49-70) 40 (35-45)
4 50 (40-62) 29 (25-34)
5 48 (38-60) 26 (21-31)
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radiotherapy advancements andbetter integrationof chemo-
therapyandradiotherapy.33 In thisanalysis,patientswithstage
I to II SCLC achieved amedian OS of 50months, with accept-
able adverse effects after chemoradiotherapy and PCI. To our
knowledge, this is the first study reportingon stage I to II SCLC
within a randomized clinical trial in the era of modern radio-
therapy. Although our findings were expected, this analysis
may benchmark chemoradiotherapy outcome and toxic ef-
fects in stage I to II SCLC, providing information that practi-
tioners can relay to their patients to aid clinical decisions.
To our knowledge, there are no randomized data to sup-
port PET staging in SCLC. Published studies34-36 found that
FDG-PETupstages apatient proportion and is associatedwith
higher sensitivity (up to 100%)andspecificity (up to83%)com-
paredwithCT.However, these results are inconsistent.37Afew
studies38,39 also demonstrated the prognostic value of pre-
treatment tumor FDG uptake in SCLC. Recent oncology prac-
tice guidelines recommend FDG-PET staging in patients with
limited-stageSCLC.22-24 Inour analysis, 58patientswith stage
I to II SCLC (67.4%) underwent staging with FDG-PET com-
paredwith309patients (56.9%)overall inCONVERT.Wefound
no statistically significant difference in OS between patients
staged with or without FDG-PET. Pretreatment tumor FDG
uptake data were unavailable. An analysis of patients staged
with orwithout FDG-PET in CONVERTwill be reported in the
future.
The roles of surgery and chemoradiotherapy in the man-
agement of early limited-stage SCLC have been heavily de-
bated for years.40 Randomized clinical trials that established
radiotherapy over surgery41 and chemoradiotherapy over tri-
modality treatment42 in limited-stage SCLC were conducted
more than 20 years ago using currently substandard surgical
and radiotherapy techniques.43 To our knowledge, there are
no contemporary randomized clinical trials comparing che-
moradiotherapywithsurgery followedbyadjuvant therapy for
limited-stage SCLC.26 Oncology practice guidelines recom-
mendsurgical resection forTNMstageT1-2N0 (National Com-
prehensive Cancer Network23) and T1-2N0,1 only after ruling
outmediastinalnodal involvement (EuropeanSociety forMedi-
cal Oncology22). Published studies13-21 have reported the role
of surgery inpatientswith limited-stage SCLC.Becauseof dif-
ferences in patient selection, staging, and changes in surgical
and supportive care standardsover time (surgical studies span
from 1991 to 2017), it is difficult to compare our findingswith
findings from those studies.
In line with the main trial,4 there was no statistically sig-
nificantdifference inOSbetweenpatientswithstage I to IISCLC
treated with once-daily or twice-daily radiotherapy. How-
ever, this studywas not designed or powered to compare trial
arms among patients with stage I to II disease. For this rea-
son, these results shouldbe regardedasdescriptiveonly.Most
patients with stage I to II SCLC (90.7%) in this analysis re-
ceived PCI, with brainmetastasis subsequently detected in 6
patients. Two retrospective series showed that patients with
surgically resected SCLC have longer OS after PCI but not pa-
tients with stage I disease.44,45 However, a recently pub-
lished population analysis21 demonstrated that patients with
pT1-2N0M0 treated with surgery alone had worse outcomes
comparedwith thosewho receivedadjuvant chemotherapyor
chemotherapy and PCI. Cranial irradiation is associated with
long-term neuropsychological toxic effects in patients
with SCLC.46Omitting PCI could be advantageous in patients
with early-stage SCLC who are likely to live longer and expe-
rience long-term adverse effects of whole-brain radio-
therapy. Neuropsychological toxic effects data after PCI were
not collected in CONVERT.
In this trial, treatmentwaswell tolerated in patients with
stage I to II SCLC, with a low incidence of severe adverse ef-
fects. Grade 3 or higher acute esophagitis was significantly
lower in patients with stage I to II SCLC compared with pa-
tients with stage III SCLC, likely because of smaller radio-
therapy treatment volumes. None of the patients with stage I
to II diseasehadgrade 3or higher acutepneumonitis. The low
incidence of severe toxic effects is a valid rationale to con-
sider future radiotherapy dose intensification trials to im-
prove outcomes in this patient group. There were also no re-
ported treatment-related deaths among patients with stage I
to II disease.
Limitations
The main limitations of this study are the unplanned nature
of the analysis with a relatively small number of patients, es-
pecially for patients with stage I SCLC. This limitation cur-
tailed the investigation of likely prognostic covariates in pa-
tients with stage I to II SCLC, such as nodal involvement (N0
vsN1), gross tumor volume, anddelivered radiotherapydose.
Conclusions
Patients with stage I to II SCLC in CONVERT achieved long-
term survival with acceptable toxic effects after chemoradio-
therapy. Concurrent chemoradiotherapy followedbyPCImay
be considered as a treatment option in this patient group. A
randomized clinical trial is ultimately required to guide the
treatment decision between a surgical and nonsurgical ap-
proach for these patients. Innovative translational studies are
also required to discover biomarkers that could improve pa-
tient selection and delivery of personalized treatment to im-
prove patient outcomes.
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